PANITUMUMAB IS A RECOMBINANT, FULLY HUMAN IgG2 MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN EGFR1*

Panitumumab, a fully human IgG2 monoclonal antibody, binding to EGFR expressed on the cell surface. ¹

EGFR is a transmembrane glycoprotein that promotes cell growth in normal epithelial cells and is expressed on the surface of various tumour cells.

KRAS and NRAS genes encode small, GTP-binding proteins involved in signal transduction. A variety of stimuli, including that from the EGFR, activate KRAS and NRAS, which in turn stimulate other intracellular proteins to promote cell proliferation, cell survival, and angiogenesis.¹

EGFR ligands bind to the receptor and activate EGFR signalling by inducing receptor autophosphorylation.1

  • A variety of stimuli, including that from EGFR, activate KRAS and NRAS, highly related members of the RAS oncogene family that encode small, GTP-binding proteins involved in signal transduction.
  • This activation stimulates other intracellular proteins to promote cell proliferation, cell survival, and angiogenesis.
Panitumumab binds to the ligand-binding domain of EGFR and competitively inhibits receptor autophosphorylation induced by all known EGFR ligands.¹

Panitumumab binds to the ligand-binding domain of EGFR and competitively inhibits receptor autophosphorylation induced by all known EGFR ligands.1

  • Binding of panitumumab to EGFR results in:1
    • EGFR receptor internalization
    • Cell growth inhibition
    • Apoptosis induction
    • Decrease in IL-8 and VEGF

Adapted from Vectibix Product Monograph.1

mid-bg

* Clinical significance has not been established.
EGFR, epidermal growth factor receptor; GTP, guanosine triphosphate; IL-8, interleukin 8; KRAS, Kirsten rat sarcoma viral oncogene homologue; NRAS, Neuroblastoma RAS viral oncogene homologue; RAS, Rat sarcoma viral oncogene homologue; VEGF, vascular endothelial growth factor.